These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 23236232)

  • 1. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon 9 Mutation of
    Seo AN; Kang BW; Bae HI; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Jeon SW; Kang H; Kim JG
    Anticancer Res; 2019 Apr; 39(4):2145-2154. PubMed ID: 30952761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations.
    Wu MS; Shun CT; Wu CC; Hsu TY; Lin MT; Chang MC; Wang HP; Lin JT
    Gastroenterology; 2000 Jun; 118(6):1031-8. PubMed ID: 10833477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
    Zhou H; Tan S; Li H; Lin X
    Mol Med Rep; 2019 Mar; 19(3):2125-2136. PubMed ID: 30747208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
    Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
    Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer].
    Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
    Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
    Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
    Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
    Yang SX; Polley E; Lipkowitz S
    Cancer Treat Rev; 2016 Apr; 45():87-96. PubMed ID: 26995633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
    Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
    Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without
    Fang WL; Huang KH; Chang SC; Lin CH; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
    Oncologist; 2019 Sep; 24(9):e845-e853. PubMed ID: 30796154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers.
    Zhang YW; He D; Tan C; Dong M; Zhou L; Shao CK
    Pathol Res Pract; 2019 Nov; 215(11):152675. PubMed ID: 31594682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
    Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
    Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
    Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
    JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.